Publications Search

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

Trivedi K, Le V, Nelson JR. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention. Postgrad Med. 2020; epub ahead of print.

Ferrières J, Bataille V, Puymirat E, Schiele F, Simon T, Danchin N, for the FAST-MI investigators. Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice? Clin Cardiol. 2020;1-6.

Hilleman DE, Wiggins BS, Bottorff MB. A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.” Adv Ther. 2020; epub ahead of print.

Nelson AJ, Navar A, Mulder H, Wojdyla D, Philip S, Granowitz C, Peterson ED, Pagidipati NJ. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial). Am J Cardiol. 2020; epub ahead of print.

Budoff MJ, Muhlestein JB, Bhatt DL, et al. Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: A prospective, placebo-controlled randomized trial (EVAPORATE): Interim Results [published online ahead of print, 2020 Jul 1]. Cardiovasc Res. 2020;cvaa184. doi:10.1093/cvr/cvaa184

Academy of Managed Care Pharmacy
Ballantyne C, Bhatt D, Bress A, Brinton E, Dolman S, King J, et al. Cost-effectiveness of icosapent ethyl in REDUCE-IT. Accepted abstract posted on-line due to 2020 virtual-only meeting.

Hilleman D, Teply R, Packard K. Knowledge, perceptions, and patterns of fish oil use in cardiac patients [abstract I16]. J Manag Care Spec Pharm. 2018;24(4 suppl a):S71.

Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis. J Manag Care Spec Pharm. 2018;24(4 suppl a):S70-S71.

American Academy of Family Physician
Crandell JR. Reductions in low-density lipoprotein cholesterol and particle concentration and improvements in other parameters of dyslipidemia in a statin-treated patient with persistent dyslipidemia and high cardiovascular risk following switch from EPA+DHA (omega-3-acid ethyl esters) to high-purity EPA (icosapent ethyl). Presented at: The American Academy of Family Physicians conference

American Association of Clinical Endocrinologists
Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides (≥150 mg/dL) and diabetes mellitus are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis [abstract 403]. Endocr Pract. 2018;24(suppl 1):96-97.

American College of Cardiology
DL, Miller M, Steg G, et al. EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Presented at the American College of Cardiology 2020 annual meeting (virtual).

Pisaniello AD, Nicholls SJ, Ballantyne CM, Bhatt DL, Wong ND. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. EMJ. 2020;5:29-36.